Loading…
Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan
The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors t...
Saved in:
| Published in: | Infection, genetics and evolution genetics and evolution, 2011-04, Vol.11 (3), p.640-645 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613 |
| container_end_page | 645 |
| container_issue | 3 |
| container_start_page | 640 |
| container_title | Infection, genetics and evolution |
| container_volume | 11 |
| creator | Aziz, Hafsa Gil, Muzaffar Latif Waheed, Yasir Adeeb, Uzama Raza, Abida Bilal, Iram Athar, Muhammad Amin |
| description | The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors that enable us to predict the response to antiviral treatment is very important. We prospectively studied 403 patients who received PEG-IFN alpha-2b 1.5μg/kg/body weight plus ribavirin. Treatment was administrated for 24 weeks and 48 weeks for hepatitis C virus (HCV) genotypes 3 and 1, respectively. Out of 403 treated patients, 301 patients (74.7%) showed a sustained virologic response (SVR). Seven variables (age, sex, ethnic group, pretreatment viral load, HCV genotyping and pretreatment ALT) were chosen as possible predictors of SVR and were analysed by means of univariable and multivariable logistic regression analysis. Five variables were statistically significant (p |
| doi_str_mv | 10.1016/j.meegid.2011.01.022 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_860188739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567134811000256</els_id><sourcerecordid>860188739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613</originalsourceid><addsrcrecordid>eNp9kFGL1DAQx4so3nn6DUTzIj51TdI2aV8EWU7v4MADPV_DNJksWdtkTdKF-_Zm6apvwkDC8Jv8J7-qes3ohlEmPuw3M-LOmQ2njG1oKc6fVJesE7KWvJNPz3fWtP1F9SKlPaVMUt4_ry44a5hoe3lZPV4fYVogu-BJsOQQw86HlJ0mFnQOMREbIrnHHbn1GaPFWECYLNR8JIdpSSS6EY4uOk9yRMgz-kwKc7P9QZy3qDMacigBpZ9Kh9zDT5cy-JfVMwtTwlfn86p6-Hz9fXtT3339crv9dFfrlnW5xhZBAmInoTO9Hg0fhoFTTqk2aIZRakmFsNBwzsU4UjFq21grZG8ktII1V9X79d3yt18LpqxmlzROE3gMS1K9oKzvZTMUsl1JHUNKEa06RDdDfFSMqpNztVerc3VyrmgpzsvYm3PAMs5o_g79kVyAd2cAki7uInjt0j-upWLg7Yl7u3IWgoJdLMzDt5LUUUpbWfIL8XElsAg7Oowq6SJWo3GxmFYmuP_v-hulDKwv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860188739</pqid></control><display><type>article</type><title>Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Aziz, Hafsa ; Gil, Muzaffar Latif ; Waheed, Yasir ; Adeeb, Uzama ; Raza, Abida ; Bilal, Iram ; Athar, Muhammad Amin</creator><creatorcontrib>Aziz, Hafsa ; Gil, Muzaffar Latif ; Waheed, Yasir ; Adeeb, Uzama ; Raza, Abida ; Bilal, Iram ; Athar, Muhammad Amin</creatorcontrib><description>The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors that enable us to predict the response to antiviral treatment is very important. We prospectively studied 403 patients who received PEG-IFN alpha-2b 1.5μg/kg/body weight plus ribavirin. Treatment was administrated for 24 weeks and 48 weeks for hepatitis C virus (HCV) genotypes 3 and 1, respectively. Out of 403 treated patients, 301 patients (74.7%) showed a sustained virologic response (SVR). Seven variables (age, sex, ethnic group, pretreatment viral load, HCV genotyping and pretreatment ALT) were chosen as possible predictors of SVR and were analysed by means of univariable and multivariable logistic regression analysis. Five variables were statistically significant (p<0.005) on univariable analysis: age, ethnic group, pretreatment viral load, response rate at week 4, and HCV genotype. In multivariable analysis independent factors associated with SVR were low pretreatment viral load (1.97; 95%CI, 1.06–3.66; p=0.03) and attainment of rapid virological response (RVR) (7.19; 95%CI, 4.15–12.45; p<0.001).
Our findings support the association between viral load and SVR to PEG-IFN-alpha-2b plus ribavirin therapy. No achievement of RVR is an unfavorable marker for SVR. These findings suggest that all patients considered for treatment should have quantification of serum HCV RNA levels. The result can be used to counsel patients on the likelihood of achieving SVR and may influence the patient's decision on treatment. Future studies should confirm and explore this observation in other ethnic groups and in relation to HCV genotypes 1 and 3.</description><identifier>ISSN: 1567-1348</identifier><identifier>EISSN: 1567-7257</identifier><identifier>DOI: 10.1016/j.meegid.2011.01.022</identifier><identifier>PMID: 21316487</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adult ; Aged ; alanine transaminase ; ALT ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; blood serum ; body weight ; chronic hepatitis C ; counseling ; Drug Therapy, Combination ; Epidemiology. Vaccinations ; Female ; General aspects ; genotype ; genotyping ; HCV ; Hepacivirus ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - epidemiology ; Humans ; Infectious diseases ; interferon-alpha ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; nationalities and ethnic groups ; Pakistan ; Pakistan - epidemiology ; patients ; PEG-interferon ; Pharmacology. Drug treatments ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; Prognosis ; Recombinant Proteins ; regression analysis ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; ribonucleosides ; RNA ; RVR ; SVR ; therapeutics ; Treatment Outcome ; viral load ; viruses ; Young Adult</subject><ispartof>Infection, genetics and evolution, 2011-04, Vol.11 (3), p.640-645</ispartof><rights>2011 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613</citedby><cites>FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24069247$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21316487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aziz, Hafsa</creatorcontrib><creatorcontrib>Gil, Muzaffar Latif</creatorcontrib><creatorcontrib>Waheed, Yasir</creatorcontrib><creatorcontrib>Adeeb, Uzama</creatorcontrib><creatorcontrib>Raza, Abida</creatorcontrib><creatorcontrib>Bilal, Iram</creatorcontrib><creatorcontrib>Athar, Muhammad Amin</creatorcontrib><title>Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan</title><title>Infection, genetics and evolution</title><addtitle>Infect Genet Evol</addtitle><description>The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors that enable us to predict the response to antiviral treatment is very important. We prospectively studied 403 patients who received PEG-IFN alpha-2b 1.5μg/kg/body weight plus ribavirin. Treatment was administrated for 24 weeks and 48 weeks for hepatitis C virus (HCV) genotypes 3 and 1, respectively. Out of 403 treated patients, 301 patients (74.7%) showed a sustained virologic response (SVR). Seven variables (age, sex, ethnic group, pretreatment viral load, HCV genotyping and pretreatment ALT) were chosen as possible predictors of SVR and were analysed by means of univariable and multivariable logistic regression analysis. Five variables were statistically significant (p<0.005) on univariable analysis: age, ethnic group, pretreatment viral load, response rate at week 4, and HCV genotype. In multivariable analysis independent factors associated with SVR were low pretreatment viral load (1.97; 95%CI, 1.06–3.66; p=0.03) and attainment of rapid virological response (RVR) (7.19; 95%CI, 4.15–12.45; p<0.001).
Our findings support the association between viral load and SVR to PEG-IFN-alpha-2b plus ribavirin therapy. No achievement of RVR is an unfavorable marker for SVR. These findings suggest that all patients considered for treatment should have quantification of serum HCV RNA levels. The result can be used to counsel patients on the likelihood of achieving SVR and may influence the patient's decision on treatment. Future studies should confirm and explore this observation in other ethnic groups and in relation to HCV genotypes 1 and 3.</description><subject>Adult</subject><subject>Aged</subject><subject>alanine transaminase</subject><subject>ALT</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>blood serum</subject><subject>body weight</subject><subject>chronic hepatitis C</subject><subject>counseling</subject><subject>Drug Therapy, Combination</subject><subject>Epidemiology. Vaccinations</subject><subject>Female</subject><subject>General aspects</subject><subject>genotype</subject><subject>genotyping</subject><subject>HCV</subject><subject>Hepacivirus</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - epidemiology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>interferon-alpha</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>nationalities and ethnic groups</subject><subject>Pakistan</subject><subject>Pakistan - epidemiology</subject><subject>patients</subject><subject>PEG-interferon</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Prognosis</subject><subject>Recombinant Proteins</subject><subject>regression analysis</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>ribonucleosides</subject><subject>RNA</subject><subject>RVR</subject><subject>SVR</subject><subject>therapeutics</subject><subject>Treatment Outcome</subject><subject>viral load</subject><subject>viruses</subject><subject>Young Adult</subject><issn>1567-1348</issn><issn>1567-7257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kFGL1DAQx4so3nn6DUTzIj51TdI2aV8EWU7v4MADPV_DNJksWdtkTdKF-_Zm6apvwkDC8Jv8J7-qes3ohlEmPuw3M-LOmQ2njG1oKc6fVJesE7KWvJNPz3fWtP1F9SKlPaVMUt4_ry44a5hoe3lZPV4fYVogu-BJsOQQw86HlJ0mFnQOMREbIrnHHbn1GaPFWECYLNR8JIdpSSS6EY4uOk9yRMgz-kwKc7P9QZy3qDMacigBpZ9Kh9zDT5cy-JfVMwtTwlfn86p6-Hz9fXtT3339crv9dFfrlnW5xhZBAmInoTO9Hg0fhoFTTqk2aIZRakmFsNBwzsU4UjFq21grZG8ktII1V9X79d3yt18LpqxmlzROE3gMS1K9oKzvZTMUsl1JHUNKEa06RDdDfFSMqpNztVerc3VyrmgpzsvYm3PAMs5o_g79kVyAd2cAki7uInjt0j-upWLg7Yl7u3IWgoJdLMzDt5LUUUpbWfIL8XElsAg7Oowq6SJWo3GxmFYmuP_v-hulDKwv</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Aziz, Hafsa</creator><creator>Gil, Muzaffar Latif</creator><creator>Waheed, Yasir</creator><creator>Adeeb, Uzama</creator><creator>Raza, Abida</creator><creator>Bilal, Iram</creator><creator>Athar, Muhammad Amin</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan</title><author>Aziz, Hafsa ; Gil, Muzaffar Latif ; Waheed, Yasir ; Adeeb, Uzama ; Raza, Abida ; Bilal, Iram ; Athar, Muhammad Amin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>alanine transaminase</topic><topic>ALT</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>blood serum</topic><topic>body weight</topic><topic>chronic hepatitis C</topic><topic>counseling</topic><topic>Drug Therapy, Combination</topic><topic>Epidemiology. Vaccinations</topic><topic>Female</topic><topic>General aspects</topic><topic>genotype</topic><topic>genotyping</topic><topic>HCV</topic><topic>Hepacivirus</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - epidemiology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>interferon-alpha</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>nationalities and ethnic groups</topic><topic>Pakistan</topic><topic>Pakistan - epidemiology</topic><topic>patients</topic><topic>PEG-interferon</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Prognosis</topic><topic>Recombinant Proteins</topic><topic>regression analysis</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>ribonucleosides</topic><topic>RNA</topic><topic>RVR</topic><topic>SVR</topic><topic>therapeutics</topic><topic>Treatment Outcome</topic><topic>viral load</topic><topic>viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aziz, Hafsa</creatorcontrib><creatorcontrib>Gil, Muzaffar Latif</creatorcontrib><creatorcontrib>Waheed, Yasir</creatorcontrib><creatorcontrib>Adeeb, Uzama</creatorcontrib><creatorcontrib>Raza, Abida</creatorcontrib><creatorcontrib>Bilal, Iram</creatorcontrib><creatorcontrib>Athar, Muhammad Amin</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Infection, genetics and evolution</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aziz, Hafsa</au><au>Gil, Muzaffar Latif</au><au>Waheed, Yasir</au><au>Adeeb, Uzama</au><au>Raza, Abida</au><au>Bilal, Iram</au><au>Athar, Muhammad Amin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan</atitle><jtitle>Infection, genetics and evolution</jtitle><addtitle>Infect Genet Evol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>11</volume><issue>3</issue><spage>640</spage><epage>645</epage><pages>640-645</pages><issn>1567-1348</issn><eissn>1567-7257</eissn><abstract>The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors that enable us to predict the response to antiviral treatment is very important. We prospectively studied 403 patients who received PEG-IFN alpha-2b 1.5μg/kg/body weight plus ribavirin. Treatment was administrated for 24 weeks and 48 weeks for hepatitis C virus (HCV) genotypes 3 and 1, respectively. Out of 403 treated patients, 301 patients (74.7%) showed a sustained virologic response (SVR). Seven variables (age, sex, ethnic group, pretreatment viral load, HCV genotyping and pretreatment ALT) were chosen as possible predictors of SVR and were analysed by means of univariable and multivariable logistic regression analysis. Five variables were statistically significant (p<0.005) on univariable analysis: age, ethnic group, pretreatment viral load, response rate at week 4, and HCV genotype. In multivariable analysis independent factors associated with SVR were low pretreatment viral load (1.97; 95%CI, 1.06–3.66; p=0.03) and attainment of rapid virological response (RVR) (7.19; 95%CI, 4.15–12.45; p<0.001).
Our findings support the association between viral load and SVR to PEG-IFN-alpha-2b plus ribavirin therapy. No achievement of RVR is an unfavorable marker for SVR. These findings suggest that all patients considered for treatment should have quantification of serum HCV RNA levels. The result can be used to counsel patients on the likelihood of achieving SVR and may influence the patient's decision on treatment. Future studies should confirm and explore this observation in other ethnic groups and in relation to HCV genotypes 1 and 3.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>21316487</pmid><doi>10.1016/j.meegid.2011.01.022</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-1348 |
| ispartof | Infection, genetics and evolution, 2011-04, Vol.11 (3), p.640-645 |
| issn | 1567-1348 1567-7257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_860188739 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adult Aged alanine transaminase ALT Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Biological and medical sciences blood serum body weight chronic hepatitis C counseling Drug Therapy, Combination Epidemiology. Vaccinations Female General aspects genotype genotyping HCV Hepacivirus Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology Humans Infectious diseases interferon-alpha Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Multivariate Analysis nationalities and ethnic groups Pakistan Pakistan - epidemiology patients PEG-interferon Pharmacology. Drug treatments Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Prognosis Recombinant Proteins regression analysis Ribavirin - adverse effects Ribavirin - therapeutic use ribonucleosides RNA RVR SVR therapeutics Treatment Outcome viral load viruses Young Adult |
| title | Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A06%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20prognostic%20factors%20for%20Peg%20Interferon%20alfa-2b%20plus%20ribavirin%20treatment%20on%20HCV%20infected%20patients%20in%20Pakistan&rft.jtitle=Infection,%20genetics%20and%20evolution&rft.au=Aziz,%20Hafsa&rft.date=2011-04-01&rft.volume=11&rft.issue=3&rft.spage=640&rft.epage=645&rft.pages=640-645&rft.issn=1567-1348&rft.eissn=1567-7257&rft_id=info:doi/10.1016/j.meegid.2011.01.022&rft_dat=%3Cproquest_cross%3E860188739%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c415t-e4ea7aee57a5d8cbd299920200cded9b7c7066fa32226bb06bcf3ff678d7a4613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=860188739&rft_id=info:pmid/21316487&rfr_iscdi=true |